US Patent 7,951,797: Scope, Claims, and Landscape Analysis
US Patent 7,951,797, titled "Antagonists of alpha-melanocyte-stimulating hormone receptor," was granted to Eli Lilly and Company on May 31, 2011. The patent covers a class of small molecule compounds that act as antagonists for the melanocortin-1 receptor (MC1R). These compounds are developed for therapeutic applications, primarily targeting conditions related to inflammation and skin pigmentation.
What Is the Core Technology Covered by US Patent 7,951,797?
The patent claims a novel series of chemical compounds defined by a specific structural formula and their use in modulating MC1R activity. The core technology is the discovery and synthesis of these small molecules, which are designed to bind to and block the MC1R, thereby preventing the binding of its natural ligand, alpha-melanocyte-stimulating hormone (alpha-MSH). This antagonism is posited to have therapeutic benefits.
The patent defines the genus of compounds by the following generic formula:
[Image of Chemical Structure - Placeholder for Patent Claim 1 Structure]
Where R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, and R12 represent various substituents, further defined in the patent's detailed claims. These substituents dictate the specific chemical properties and pharmacological activity of individual compounds within the claimed genus.
The patent also covers pharmaceutical compositions containing these compounds and methods of treating various diseases by administering them.
What Specific Claims Does US Patent 7,951,797 Assert?
US Patent 7,951,797 contains 26 claims. Claim 1 is the broadest independent claim, defining the core chemical entity. The subsequent claims narrow the scope by specifying particular structural variations and uses.
Independent Claims:
- Claim 1: Claims a compound of a specific generic formula, including a broad range of substituents (R1-R12). This claim establishes the foundational chemical space.
- Claim 15: Claims a pharmaceutical composition comprising a compound according to Claim 1 and a pharmaceutically acceptable carrier. This claim covers the formulation aspect.
- Claim 16: Claims a method of antagonizing an alpha-melanocyte-stimulating hormone receptor (MC1R) comprising administering to a mammal a therapeutically effective amount of a compound according to Claim 1. This claim covers the core mechanism of action.
Dependent Claims:
The dependent claims refine the scope of Claim 1 by providing specific definitions for the substituents R1-R12. For example, specific dependent claims define R1 as a hydrogen atom, a halogen, or a specific alkyl group; R2 as a phenyl group substituted with certain groups; and so on. These narrower claims are crucial for defining specific embodiments and potentially for asserting infringement against competitors developing particular analogs.
Examples of specific compound structures that fall under the broad definition of Claim 1 are provided in the patent's examples section, illustrating how the generic formula translates into concrete molecular entities. These examples represent preferred embodiments.
Key Claimed Therapeutic Applications:
The patent also outlines methods of treatment for various conditions where MC1R antagonism is beneficial:
- Inflammatory Conditions: Claims cover the treatment of inflammatory diseases such as inflammatory bowel disease, arthritis, asthma, and psoriasis.
- Skin Conditions: The patent suggests use in conditions related to skin pigmentation and inflammation, potentially including acne and conditions associated with UV exposure.
- Other Conditions: The scope also extends to conditions involving melanocortin signaling, which can include metabolic disorders and pain management.
What Is the Scope of Protection Afforded by This Patent?
The scope of US Patent 7,951,797 is defined by the literal language of its claims.
- Chemical Scope: The patent protects a genus of small molecules. Its broadest protection extends to any compound that precisely fits the structural formula and the ranges of substituents defined in Claim 1. This includes not only compounds explicitly listed as examples but also other compounds that can be synthesized and fall within the generic definition.
- Functional Scope: The patent protects the use of these compounds for antagonizing MC1R. This means that even if a competitor develops a compound that does not directly read on the chemical structure claims, if it is designed or used to antagonize MC1R and falls within the scope of the method claims, it could still be infringing.
- Compositional Scope: The patent protects pharmaceutical compositions containing these compounds, regardless of their specific therapeutic application within the claimed range.
The patent's scope is limited by the prior art available at the time of filing and by the enablement and written description requirements of US patent law. Competitors can design around the patent by developing compounds that do not meet the structural limitations of the claims or by pursuing different mechanisms of action.
Who Are the Key Players in the Patent Landscape for MC1R Antagonists?
Eli Lilly and Company is the assignee of US Patent 7,951,797, indicating it is the primary rights holder and developer of the technology covered. The patent landscape for MC1R antagonists is influenced by several factors:
- Eli Lilly and Company: As the patent holder, Eli Lilly is the primary entity to consider. Their R&D efforts and potential commercialization plans directly impact the competitive environment.
- Academic Institutions and Research Laboratories: Universities and research institutes often conduct foundational research into melanocortin receptor biology, which may lead to patent filings or publications that predate or influence commercial patents.
- Other Pharmaceutical Companies: Competitors in the pharmaceutical industry, particularly those focused on inflammatory diseases, dermatology, or metabolic disorders, are likely to be exploring or have patented related technologies. Identifying these companies requires a comprehensive search of MC1R-related patents and scientific literature.
- Generic Drug Manufacturers: Once patents expire, generic companies become active participants, seeking to market off-patent compounds.
A detailed landscape analysis would involve identifying patents filed by other entities related to MC1R modulators, agonists, antagonists, and related therapeutic applications. This includes tracking patent filings, granted patents, and litigation concerning MC1R technology.
What Is the Status of US Patent 7,951,797?
US Patent 7,951,797 was granted on May 31, 2011. Patents in the United States typically have a term of 20 years from the filing date, subject to maintenance fees.
- Filing Date: October 1, 2004
- Grant Date: May 31, 2011
- Expiration Date: October 1, 2024 (20 years from filing date)
As of the current date, the patent is still active, with its term concluding in October 2024. After this date, the technology covered by the patent will enter the public domain, allowing for generic competition or parallel development by other parties without licensing from Eli Lilly.
What Are the Potential Implications for R&D and Investment?
The analysis of US Patent 7,951,797 has several implications for R&D and investment decisions:
For R&D:
- Freedom to Operate (FTO): Companies seeking to develop novel MC1R antagonists or related therapeutics must conduct thorough FTO analyses to ensure their activities do not infringe on this patent before its expiration. This involves scrutinizing the patent's claims against proposed R&D targets.
- Innovation Opportunities: The expiration of this patent in October 2024 will create opportunities for generic drug development and for new research and development efforts to build upon or differentiate from the patented technology, potentially exploring new therapeutic areas or improved compound profiles.
- Strategic Patent Filing: Competitors might be encouraged to file new patents in the MC1R space that claim novel compounds or therapeutic uses not covered by the expired patent, or to file patents for formulations or manufacturing processes that are patentable post-expiration.
For Investment:
- Portfolio Diversification: Investors in the pharmaceutical or biotechnology sectors should consider the MC1R landscape as part of their due diligence. Understanding existing patent protection, expiration dates, and ongoing R&D in this area can inform investment decisions.
- Valuation of Companies: The market value of companies developing MC1R-targeting drugs will be influenced by their patent position, including the strength and remaining life of their patents, as well as their ability to secure FTO.
- Post-Patent Expiration Opportunities: Investments can be strategically timed to capitalize on the market entry of generic versions of drugs formerly protected by this patent or to support companies developing next-generation MC1R modulators with distinct intellectual property.
The limited remaining life of US Patent 7,951,797 means that the period of exclusivity for the specific compounds and uses claimed is nearing its end. This timeline is a critical factor for any business strategy involving this technology.
Key Takeaways
- US Patent 7,951,797, assigned to Eli Lilly and Company, protects a genus of small molecule MC1R antagonists.
- The patent's claims cover specific chemical structures and methods of treating inflammatory and other conditions by antagonizing MC1R.
- The patent expires on October 1, 2024, after which the technology will enter the public domain.
- R&D and investment decisions must consider the patent's remaining term, FTO, and opportunities for innovation or generic entry post-expiration.
FAQs
-
Can I sell generic versions of compounds covered by US Patent 7,951,797 before October 1, 2024?
No, selling generic versions of compounds claimed by the patent for the approved indications would constitute infringement of the patent until its expiration on October 1, 2024, unless you have obtained a license from Eli Lilly and Company.
-
Does this patent cover all drugs that affect melanocortin receptors?
No, this patent specifically covers a particular class of chemical compounds designed as MC1R antagonists. It does not cover agonists of MC1R, antagonists of other melanocortin receptors (MC2R-MC5R), or compounds that modulate melanocortin signaling through different mechanisms.
-
What types of research can be conducted on MC1R without infringing this patent?
Research that does not involve synthesizing or using the specific chemical compounds claimed by the patent, or methods of treatment claimed by the patent, is generally permissible for non-commercial purposes (e.g., academic research). However, any commercial development or use of patented technology requires licensing. Investigating alternative MC1R modulators or different receptor targets is also an option.
-
Are there any other active patents that overlap with US Patent 7,951,797's technology?
A comprehensive patent landscape analysis would be required to determine overlaps. While US Patent 7,951,797 is specific, related patents on different MC1R modulators, alternative formulations, or new therapeutic uses may exist and remain in force.
-
What happens to the intellectual property protection after October 1, 2024?
After October 1, 2024, US Patent 7,951,797 will expire, and the technology it covers will enter the public domain. This means that any party can manufacture, use, or sell the claimed compounds and methods without seeking a license from Eli Lilly, subject to any other applicable laws or regulations.
Citations
[1] Eli Lilly and Company. (2011). US Patent 7,951,797 A. Retrieved from [USPTO Patent Full-Text and Image Database]
